CX-4945 in Viral Community Acquired Pneumonia
A legfontosabb adatok
- Ki végzi
- Senhwa Biosciences, Inc.
- Hol
- Tajvan7 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 45 fő vett részt
- Kezdés
- 2024. márc. 20.
- Befejezés
- 2025. ápr. 22.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- CX-4945 (SARS-CoV-2 domain)
- Placebo (SARS-CoV-2 domain)
- CX-4945 (Influenza virus domain)
- Placebo (Influenza virus domain)
- A regiszteradat frissítve
- 2026. január 8.
- Miért állt le
- The trial ended early in March 2025 due to changes in disease epidemiology, affecting patient availability and recruitment feasibility.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 32 feltétel megnézéseKevesebb
Ki vehet részt
- Not currently hospitalized
- Males or females aged ≥ 18 years at the time of signing the informed consent form (ICF)
- Patients diagnosed with viral pneumonia, as determined by the investigator, who exhibit any of the subsequent criteria: presence of respiratory symptoms or fever (ear temperature ≥ 38 °C, base of the tongue temperature ≥ 37.5 °C, or axillary temperature ≥ 37 °C)
- With a pneumonia severity index (PSI) of risk class II or III
- Oxygen saturation measured by pulse oximetry (SpO2) ≥ 94% on room air at sea level
- Positive test for SARS-CoV-2 or influenza virus infection, confirmed by rapid diagnostic test (excluding cases where both SARS-CoV-2 and influenza virus are positive)
- Confirmed lower respiratory tract infection by X-ray
- At screening, subjects capable of childbearing must provide a negative serum or urine pregnancy test. These subjects must also commit to adhering to the study-specified contraceptive methods throughout the study duration; Notes: Acceptable contraceptive methods include:; Established use of oral, injected or implanted hormonal methods of contraception; Placement of an intrauterine device (IUD) or intrauterine system (IUS); Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps)
- The participant (or legal representative) agrees and is able to adhere to study protocol-stated requirements, instructions, and restrictions in the investigator's judgement. Furthermore, the participant is capable of understanding and has signed the IRB-approved Informed Consent Form (ICF)
- With at least two of the risk factors listed below: Age ≥ 50 years-old; cancer and a life expectancy of ≥ 6 months; HIV infection; immunocompromised patient; congestive heart failure (CHF), or coronary artery disease (CAD), or cardiomyopathies; chronic kidney disease (CKD); chronic liver disease; chronic lung disease; diabetes mellitus (DM); body mass index (BMI) > 25 kg/m2; asthma; cerebrovascular disease; cystic fibrosis; dementia; or current and former smoker
Ki nem vehet részt
- Subject received investigational treatment within 30 days prior to the study, or concurrent use of another investigational drug
- Subjects received warfarin within 14 days prior to screening or intend to during the screening or treatment phase
- Have received treatment with a SARS-CoV-2 specific monoclonal antibody
- Have received convalescent COVID-19 plasma treatment
- Concurrent use of baricitinib
- Subject has a history of severe renal disease (required phosphate binders or dialysis)
- Subject showing signs of respiratory failure and mechanical ventilation is required
- Known active tuberculosis
- Current documented bacterial infection
- Subject who has taken an antiviral agent against respiratory viral infection for a continuous duration of more than 24 hours before screening
- Subject is with active gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis
- History of allergic reactions to any of the ingredients or components used in the manufacture of CX-4945
- Any physical findings or illness history that may compromise study results or increase patient risk, as determined by the investigator
- Subject with hepatitis B and/or hepatitis C disease, unless the subject has an aspartate aminotransferase (AST) level ranging from 8 to 31 U/L and an alanine aminotransferase (ALT) level from 0 to 41 U/L
- ALT or AST levels > 5 times upper limit of normal (ULN)
- eGFR <30 mL/min/1.73m2 (calculated by the MDRD formula)
- Absolute neutrophil count (ANC) <1000/μL
- Subject has chronic diarrhea, characterized by three or more loose stools daily for a minimum of four weeks
- High likelihood of mortality within the next 48 hours, as assessed by the investigator
- Subject with liver cirrhosis
- Subject has a documented anaphylactic reaction, regardless of cause
- Women who are pregnant or breastfeeding, or planning pregnancy during the study; Note: Men and women of reproductive potential must commit to effective contraception methods or abstinence during the study. Any resulting pregnancies or suspected pregnancies must be reported to the treating physician immediately
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated pneumonia. The subjects will be recruited into two domains, including SARS-CoV-2 and influenza virus domains. The study will compare the efficacy of Standard of Care (SOC) combined with CX-4945 against SOC paired with a placebo, utilizing a 1:1 allocation ratio in each domain.
A vizsgálat 4 csoportja
- SARS-CoV-2 domain: CX-4945 (400 mg BID for 5 days) +SOCA vizsgált kezelés
Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.
Kezelés: CX-4945 (SARS-CoV-2 domain)
- SARS-CoV-2 domain: Placebo + SOCPlacebo, összehasonlításként
Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.
Kezelés: Placebo (SARS-CoV-2 domain)
- Influenza virus domain: CX-4945 (400 mg BID for 5 days) +SOCA vizsgált kezelés
Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.
Kezelés: CX-4945 (Influenza virus domain)
- Influenza virus domain: Placebo + SOCPlacebo, összehasonlításként
Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.
Kezelés: Placebo (Influenza virus domain)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Evaluation of the Safety and Efficacy of Silmitasertib (CX-4945) in Combination With Standard of Care (SOC) for Treating Patients With Community-Acquired Pneumonia (CAP) Associated With SARS-CoV-2 and Influenza Viral Infections
- A regiszteradat frissítve
- 2026. január 8.